Recruiting
Phase 2

Cyclophosphamide & Sirolimus

Sponsor:

University of Michigan Rogel Cancer Center

Code:

NCT03099356

Conditions

Metastatic Thyroid Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Cyclophosphamide

Sirolimus

Study Details

Brief summary:

This study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the treatment of metastatic differentiated thyroid cancer. Patients will be treated with Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19. Cycle length will be 28 days. Patients will be monitored closely for toxicity and undergo imaging to evaluate efficacy once every 2 cycles.

Conditions

Metastatic Thyroid Cancer

Study ID

NCT03099356

Start date

Apr 27, 2017

Status verified date

Jul, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Histologically documented differentiated thyroid cancer with or without metastases, not amenable to curative treatment; or the patient has documented refusal of curative treatment
  • Measurable disease (>10 mm) and have progression of disease based on RECIST criteria. Previously irradiated tumor lesions are not considered measurable unless they have progressed since radiation.
  • Previous failure of Iodine-131 (131I) therapy or not candidates to receive 131I as assessed by treating physician.
  • Age ≥ 18 years
  • ECOG (Eastern Cooperative Oncology Group) performance status 0-2
  • Life expectance of ≥ 12 weeks
  • 131I therapy not allowed within 24 weeks before entry (4 weeks if negative post-treatment scan)
  • Adequate organ and marrow function
  • Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment
  • Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment
  • Willingness and ability to comply with scheduled visits, treatment plans, including willingness to take study medication, laboratory tests, and other study procedures

Exclusion Criteria:

  • Inability to obtain Foundation One testing on archival tissue, or, lack of previous Next Generation Sequencing
  • Chemotherapy, tyrosine kinase inhibitor, or radiation therapy within 4 weeks
  • Prior experimental therapy within 4 weeks of planned start of this trial
  • 131I therapy within 24 weeks before entry (4 weeks if negative post-treatment scan)
  • Previous treatment with an mTOR inhibitor
  • Patients who are currently receiving treatment with strong inhibitors or inducers of CYP3A4 or P-glycoprotein that cannot be discontinued at least one week prior to the start of treatment with Cyclophosphamide and Sirolimus
  • Impairment of GI (gastrointestinal) function or GI disease that may significantly alter the absorption of study medications (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection) including dependence on a G-Tube for administration of medications.
  • A serious uncontrolled medical disorder or active infection that would impair their ability to receive study treatment
  • Patients with known sensitivities to either cyclophosphamide and/or sirolimus
  • Patients with known urinary outflow obstruction
  • Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol
  • Patients (male and female) having procreative potential who are not willing or not able to use adequate contraception or practicing abstinence
  • Women who are pregnant or breast-feeding
  • Patients residing in prison

Study Design

Enrollment

22 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Cyclophosphamide and Sirolimus

Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19

Interventions

Cyclophosphamide

Cyclophosphamide 100 mg, PO, days 1-5 and 15-19

Sirolimus

Sirolimus 4 mg, PO, days 1-28

Primary outcome measure

  • Percentage of patients that respond to treatment [ Time Frame: Patients will be followed for response until progression or up to 2 Years ]

Central Contacts and Locations

Central contacts

Cancer AnswerLine

1-800-865-1125canceranswerline@umich.edu

Paul Swiecicki, M.D.

pswiecic@med.umich.edu

Locations

University of Michigan Cancer Center

Recruiting

Ann Arbor, Michigan, United States, 48109

Contacts

Paul Swiecicki, M.D.

pswiecic@med.umich.edu

Francis Worden, M.D.

734-936-0453fworden@umich.edu

Principal Investigator:

Paul Swieciki, M.D.

More Information

Sponsor

University of Michigan Rogel Cancer Center

Last update posted

Jul 31, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of Michigan Rogel Cancer Center on 2026-07-31.